Supplemental Figure 22. Boxplots showing the relative percentage of T/NK cells expressing immune checkpoint receptors in acral and non-acral (cutaneous) melanoma samples.


ADORA2A
Wilcoxon, p = 0.0089
% Cell with Expression
3
2
1
0
n=8
n=5
Acral
Cutaneous
Site


NT5E
Wilcoxon, p = 0.0089
% Cell with Expression
3
2
1
0
n=8
n=5
Acral
Cutaneous
Site


ENTPD1
Wilcoxon, p = 0.057
30
20
10
0
% Cell with Expression
n=8
n=5
Acral
Cutaneous
Site


BTLA
Wilcoxon, p = 0.093
15
10
5
0
% Cell with Expression
n=8
n=5
Acral
Cutaneous
Site


CD274
Wilcoxon, p = 0.097
% Cell with Expression
3
2
1
0
n=8
n=5
Acral
Cutaneous
Site


CD276
Wilcoxon, p = 0.3
% Cell with Expression
3
2
1
0
n=8
n=5
Acral
Cutaneous
Site


CD80
Wilcoxon, p = 0.019
2.0
1.5
1.0
0.5
0.0
% Cell with Expression
n=8
n=5
Acral
Cutaneous
Site


CD86
Wilcoxon, p = 0.5
% Cell with Expression
1.5
1.0
0.5
0.0
n=8
n=5
Acral
Cutaneous
Site


CTLA4
Wilcoxon, p = 0.065
30
20
10
% Cell with Expression
n=8
n=5
Acral
Cutaneous
Site


HAVCR2
Wilcoxon, p = 0.0062
30
20
10
0
% Cell with Expression
n=8
n=5
Acral
Cutaneous
Site


IDO1
Wilcoxon, p = 1
0.4
0.3
0.2
0.1
0.0
% Cell with Expression
n=8
n=5
Acral
Cutaneous
Site


KIR2DL1
Wilcoxon, p = 0.56
% Cell with Expression
5
4
3
2
1
0
n=8
n=5
Acral
Cutaneous
Site


KIR2DL3
Wilcoxon, p = 0.94
10.0
7.5
5.0
2.5
0.0
% Cell with Expression
n=8
n=5
Acral
Cutaneous
Site


KIR2DL4
Wilcoxon, p = 0.66
15
10
5
0
% Cell with Expression
n=8
n=5
Acral
Cutaneous
Site


KIR3DL1
Wilcoxon, p = 0.19
1.5
1.0
0.5
0.0
% Cell with Expression
n=8
n=5
Acral
Cutaneous
Site


KIR3DL2
Wilcoxon, p = 0.16
% Cell with Expression
3
2
1
0
n=8
n=5
Acral
Cutaneous
Site


KIR3DL3
0.12
0.08
0.04
0.00
−0.04
% Cell with Expression
Wilcoxon, p = 0.29
n=8
n=5
Acral
Cutaneous
Site


LAG3
Wilcoxon, p = 0.35
40
30
20
10
0
% Cell with Expression
n=8
n=5
Acral
Cutaneous
Site


PDCD1
Wilcoxon, p = 0.52
% Cell with Expression
20
15
10
5
0
n=8
n=5
Acral
Cutaneous
Site


VSIR
Wilcoxon, p = 0.03
35
30
25
20
15
10
% Cell with Expression
n=8
n=5
Acral
Cutaneous
Site


TIGIT
Wilcoxon, p = 0.28
% Cell with Expression
40
30
20
10
n=8
n=5
Acral
Cutaneous
Site



Supplemental Figure 23. Boxplot showing expression of NT5E in acral and non-acral cutaneous melanoma cells (Wilcoxon test).



Supplemental Figure 24. Heatmaps showing proportion of cells expressing checkpoints across cell types in individual samples of acral melanoma.



Supplemental Figure 25. Violin plots showing expression of checkpoints ADORA2A, TIGIT, and VSIR across six public datasets.